94 Chapter 5 the correlation of [89Zr]Zr-DFO-durvalumab SUVpeak with treatment response (Spearman ρ 0.67, p=0.855). [18F]FDG PET/CT Patients with an above median [18F]FDG TLG showed a significantly worse outcome compared to patients with a low [18F]FDG TLG (median PFS 1.8 versus 7.3 months, HR 2.4 (95%CI 1.1-5.4, p=0.04, Figure 6). Figure 6. Kaplan-Meier estimates of progression free survival based on [18F]FDG total lesion glycolysis dichotomized at the population median Patients with above median [18F]FDG SUVpeak showed a median PFS of 5.3 compared to 5.7 months in the below median group (HR 1.5 (95%CI 0.7-3.4, p=0.30). The [18F]FDG MTV was not associated with PFS (p=0.69) (not shown). The correlation between [18F]FDG SUVpeak and [ 18F]FDG TLG ratio with PFS after correcting for lesions <20mm is reported in Supplementary data and showed similar results as described for all lesions (Supplementary Figure S7). On a lesion level, PD-L1 CPS score did not correlate to [89Zr]Zr-DFO-durvalumab SUVpeak (Spearman ρ 0.38, p= 0.20), [89Zr]Zr-DFO-durvalumab TTB ratio (Spearman ρ -0.06, p=0.85), 18F-FDG TLG (Spearman ρ 0.40, p= 0.90) or [18F]FDG SUVpeak (Spearman ρ -0.12, p= 0.70).
RkJQdWJsaXNoZXIy MTk4NDMw